Treatment options for the management of individuals with MAFLD can lead to resolution of hepatic fibrosis, during which hepatic stellate cells undergo apoptosis, become senescent, or revert to an inactive state with diminished PDGFRβ production [64]. The gene discussed is PDGFRB; the disease is Hepatic fibrosis.